CN103396494A - 一种凝血因子ⅸ的单克隆抗体 - Google Patents
一种凝血因子ⅸ的单克隆抗体 Download PDFInfo
- Publication number
- CN103396494A CN103396494A CN2013101511508A CN201310151150A CN103396494A CN 103396494 A CN103396494 A CN 103396494A CN 2013101511508 A CN2013101511508 A CN 2013101511508A CN 201310151150 A CN201310151150 A CN 201310151150A CN 103396494 A CN103396494 A CN 103396494A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- hcl
- monoclonal antibody
- sequence table
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010076282 Factor IX Proteins 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 29
- 210000002381 plasma Anatomy 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 17
- 229920005989 resin Polymers 0.000 claims description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 13
- 238000010168 coupling process Methods 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 13
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000013016 damping Methods 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 229940019700 blood coagulation factors Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 208000030507 AIDS Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000005252 hepatitis A Diseases 0.000 abstract description 2
- 208000002672 hepatitis B Diseases 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 18
- 108090000190 Thrombin Proteins 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- 229960004072 thrombin Drugs 0.000 description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 208000009292 Hemophilia A Diseases 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 208000031220 Hemophilia Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241001529459 Enterovirus A71 Species 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 238000000749 co-immunoprecipitation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000009429 hemophilia B Diseases 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 206010050013 Abulia Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310151150.8A CN103396494B (zh) | 2013-04-27 | 2013-04-27 | 一种凝血因子ix的单克隆抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310151150.8A CN103396494B (zh) | 2013-04-27 | 2013-04-27 | 一种凝血因子ix的单克隆抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103396494A true CN103396494A (zh) | 2013-11-20 |
CN103396494B CN103396494B (zh) | 2015-04-01 |
Family
ID=49560246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310151150.8A Active CN103396494B (zh) | 2013-04-27 | 2013-04-27 | 一种凝血因子ix的单克隆抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103396494B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105294857A (zh) * | 2014-06-18 | 2016-02-03 | 上海交通大学 | 基于fix的抗原表位及其应用 |
CN105349495A (zh) * | 2015-11-17 | 2016-02-24 | 清华大学 | 抗凝血因子ix单克隆抗体的杂交瘤细胞株 |
CN110257358A (zh) * | 2019-06-10 | 2019-09-20 | 广东双林生物制药有限公司 | 一种高纯人凝血因子ix制剂的生产方法 |
CN110314414A (zh) * | 2019-07-23 | 2019-10-11 | 宝锐生物科技泰州有限公司 | 免疫亲和层析柱填料、免疫亲和层析柱、凝血因子xiii的分离纯化方法及其应用 |
CN110343181A (zh) * | 2018-04-08 | 2019-10-18 | 苏州康宁杰瑞生物科技有限公司 | 针对凝血因子ix(fix)的单域抗体 |
CN112114069A (zh) * | 2020-09-18 | 2020-12-22 | 江苏艾迪药业股份有限公司 | 凝血酶的亲和色谱柱、制备方法及应用 |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
WO2022257929A1 (zh) * | 2021-06-08 | 2022-12-15 | 上海循曜生物科技有限公司 | 新型抗栓抗体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1336178A (zh) * | 2001-08-16 | 2002-02-20 | 四川高维系统工程技术有限公司 | 凝血因子ⅸ复合物的制备方法 |
CN101663322A (zh) * | 2006-12-14 | 2010-03-03 | 株式会社未来创药研究所 | 抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断 |
US20100204452A1 (en) * | 2007-07-11 | 2010-08-12 | Novo Nordisk Health Care Ag | Purification of Factor VIII Using a Mixed-Mode or Multimodal Resin |
-
2013
- 2013-04-27 CN CN201310151150.8A patent/CN103396494B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1336178A (zh) * | 2001-08-16 | 2002-02-20 | 四川高维系统工程技术有限公司 | 凝血因子ⅸ复合物的制备方法 |
CN101663322A (zh) * | 2006-12-14 | 2010-03-03 | 株式会社未来创药研究所 | 抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断 |
US20100204452A1 (en) * | 2007-07-11 | 2010-08-12 | Novo Nordisk Health Care Ag | Purification of Factor VIII Using a Mixed-Mode or Multimodal Resin |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105294857A (zh) * | 2014-06-18 | 2016-02-03 | 上海交通大学 | 基于fix的抗原表位及其应用 |
CN105349495A (zh) * | 2015-11-17 | 2016-02-24 | 清华大学 | 抗凝血因子ix单克隆抗体的杂交瘤细胞株 |
CN105349495B (zh) * | 2015-11-17 | 2019-02-22 | 清华大学 | 抗凝血因子ix单克隆抗体的杂交瘤细胞株 |
CN110343181A (zh) * | 2018-04-08 | 2019-10-18 | 苏州康宁杰瑞生物科技有限公司 | 针对凝血因子ix(fix)的单域抗体 |
CN110343181B (zh) * | 2018-04-08 | 2022-04-08 | 苏州康宁杰瑞生物科技有限公司 | 针对凝血因子ix(fix)的单域抗体 |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
CN110257358A (zh) * | 2019-06-10 | 2019-09-20 | 广东双林生物制药有限公司 | 一种高纯人凝血因子ix制剂的生产方法 |
CN110257358B (zh) * | 2019-06-10 | 2023-05-19 | 广东双林生物制药有限公司 | 一种高纯人凝血因子ix制剂的生产方法 |
CN110314414A (zh) * | 2019-07-23 | 2019-10-11 | 宝锐生物科技泰州有限公司 | 免疫亲和层析柱填料、免疫亲和层析柱、凝血因子xiii的分离纯化方法及其应用 |
CN110314414B (zh) * | 2019-07-23 | 2021-10-19 | 宝锐生物科技泰州有限公司 | 凝血因子xiii的分离纯化方法及其应用 |
CN112114069A (zh) * | 2020-09-18 | 2020-12-22 | 江苏艾迪药业股份有限公司 | 凝血酶的亲和色谱柱、制备方法及应用 |
WO2022257929A1 (zh) * | 2021-06-08 | 2022-12-15 | 上海循曜生物科技有限公司 | 新型抗栓抗体 |
Also Published As
Publication number | Publication date |
---|---|
CN103396494B (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103396494B (zh) | 一种凝血因子ix的单克隆抗体 | |
CN101189334B (zh) | 抗cd14抗体融合蛋白质 | |
CN102725309A (zh) | 针对GPVI的新的拮抗剂抗体及其Fab片段及其用途 | |
JP7028471B2 (ja) | 第xi因子の活性部位に対するモノクローナル抗体及びその使用 | |
CN108064240A (zh) | 针对流感血凝素的人抗体 | |
US11084869B2 (en) | Antibody-mediated neutralization of Marburg virus | |
CN102143979A (zh) | 针对组织因子途径抑制剂(tfpi)的单克隆抗体 | |
CN103476800B (zh) | 融合蛋白 | |
AU2015217149A1 (en) | Novel full spectrum anti-dengue antibody | |
TW201728603A (zh) | 凝血酶抗體、其抗原結合片段及醫藥用途 | |
CN114805579B (zh) | 一种抗人ace2蛋白单克隆抗体、核酸分子及应用 | |
US20230220111A1 (en) | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
JP2023526469A (ja) | SARS-CoV-2に対する強力な中和抗体、その生成および使用 | |
CN103319593B (zh) | 一种抗StxII单克隆抗体 | |
Zhou et al. | Recombinant antibody Fab against the hypervariable region 1 of hepatitis C virus blocks the virus adsorption to susceptible cells in vitro | |
CN107043423B (zh) | 凝血酶抗体、其抗原结合片段及医药用途 | |
CN113150125A (zh) | 一种带状疱疹单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiao Yongjun Inventor after: Zeng Xiaoyan Inventor after: Zhou Minghao Inventor before: Jiao Yongjun Inventor before: Zhang Li Inventor before: Zeng Xiaoyan Inventor before: Guo Xiling Inventor before: Shi Zhiyang Inventor before: Cui Lunbiao Inventor before: Zhou Minghao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: JIAO YONGJUN ZHANG LI CENG XIAOYAN GUO XILING SHI ZHIYANG CUI LUNBIAO ZHOU MINGHAO TO: JIAO YONGJUN CENG XIAOYAN ZHOU MINGHAO |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiao Yongjun Inventor before: Jiao Yongjun Inventor before: Zeng Xiaoyan Inventor before: Zhou Minghao |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180115 Address after: 318000 528 room 528, No. 488, east section of Stadium Road, stadium, Taizhou Economic Development Zone, Zhejiang Patentee after: Zhejiang great bio Pharmaceutical Co., Ltd. Address before: No. 172 Jiangsu Road, Nanjing, Jiangsu Patentee before: Jiangsu Disease Prevention Control Central |